Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FEMY

FEMY - Femasys Inc. Stock Price, Fair Value and News

$0.57+0.02 (+3.64%)
Market Closed

14/100

FEMY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

14/100

FEMY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FEMY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FEMY Price Action

Last 7 days

7.6%

Last 30 days

14.0%

Last 90 days

-33.7%

Trailing 12 Months

-59.3%

FEMY RSI Chart

FEMY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FEMY Valuation

Market Cap

33.3M

Price/Earnings (Trailing)

-1.68

Price/Sales (Trailing)

16.17

EV/EBITDA

-2.39

Price/Free Cashflow

-1.66

FEMY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FEMY Fundamentals

FEMY Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

31.44%

Rev. Growth (Qtr)

78.22%

FEMY Earnings

Earnings (TTM)

-19.8M

Earnings Growth (Yr)

22.45%

Earnings Growth (Qtr)

8.53%

FEMY Profitability

EBT Margin

-960.23%

Return on Equity

-434.6%

Return on Assets

-121.55%

Free Cashflow Yield

-60.22%

FEMY Investor Care

Shares Dilution (1Y)

155.39%

Diluted EPS (TTM)

-0.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.7M1.9M2.1M0
20241.0M950.1K1.3M1.6M
20231.2M1.2M1.1M1.1M
20221.2M1.1M1.2M1.2M
20211.1M1.1M1.1M1.2M
20200001.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Femasys Inc.

FEMY
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
 CEO
 WEBSITEfemasys.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES34

Femasys Inc. Frequently Asked Questions

FEMY is the stock ticker symbol of Femasys Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Femasys Inc. is 33.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, FEMY's PE ratio (Price to Earnings) is -1.68 and Price to Sales (PS) ratio is 16.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FEMY PE ratio will change depending on the future growth rate expectations of investors.